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IN-VIVO ANTIPARASITIC ASSESSMENT AND TOXICITY 
EVALUATION OF Curcuma longa AGAINST THE GROWTH 
AND SURVIVAL OF Trypanosoma evansi IN MICE

Trypanosoma evansi
• First discovered by Sir Griffith Evans in Punjab India (1880)
• Haemoflagellated protozoa in both human and animals 
zoonotic vector-borne disease   
• Caused atypical human trypanosomiasis (AHT) in human and 
Surra disease in mammals (mostly livestock)
• Wide variety of vectors  worldwide distributed 
• Drug resistant in some regions  suramin, pentamidine, berenil
Vectors of Trypanosoma evansi
Horsefly /Tabanus striatus Tsetse fly / Glossina morsitans
Muscidae fly / Stomoxys spp.Horn fly / Haematobia spp.
Triatominae bug / Triatoma spp.
Buffalo leech / Hiruninaria manillensis Vampire bat / Desmodus rotundus
Another Possible Vectors of Trypanosoma evansi
Argasidae tick / Ornithordorus spp.
Documented AHT (Philippe et al. 2013)
No Location Species / Subspecies Date Identification Method Fever Treatment Outcomes
1 Ghana T. vivax 1917 Morphology ND ND ND
2 Pasteur Inst. T. b. brucei 1930 Morphology ND ND ND
3 Congo T. b. brucei 1947 Morphology Present None Self-cured
4 Ethiopia T. b. brucei 1987 Morphology ND ND Cured
5 Ghana T. b. brucei 2003 PCR Present None Self-cured
6 Ivory Coast T. congolense 1998 PCR Present Pentamidine Cured
7 India T. evansi 1977 Morphology Present Atoxyl Cured
8 Sri Lanka T. evansi 1999 Morphology Present None Self-cured
9 India T. evansi 2004 PCR Present Suramin Cured
10 India T. evansi 2005 Morphology Present None Death
11 Egypt T. evansi 2010 Morphology Present ND Cured
12 Malaysia T. lewisi 1933 Morphology Present None Self-cured
13 India T. lewisi 1974 Morphology Present None Self-cured
14 India T. lewisi 1974 Morphology Present None Self-cured
15 Gambia T. lewisi-like 2003 PCR Present Melarsoprol Cured
16 Thailand T. lewisi-like 2003 PCR Present Antibiotic Cured
17 India T. lewisi 2006 Morphology Present None Self-cured
18 India T. lewisi 2007 PCR Present Suramin Death
19 India T. lewisi 2010 PCR Present Pentamidin Cured
Outstanding antiulcer element 
in rats (Rafatullah et al, 2009)
Antivenom property of essential 
oil (Ferriera et al, 2012) 
Anti-MRSA activity of turmeric 
oil (Gupta et al, 2015)
Hepatoprotective activities 
(Arawwawala et al. 2010)
Antidiabetic activities on 
NIDDM rats (Srinivasan, 2008)
Curcuma longa : The Testimonial
In-vitro & in-vivo anticancer 
elements (Kuttan et al, 2015)
Antifungal activity of turmeric 
oil (Apisariyakul et al, 2015)
In-vitro & in-vivo antiplasmodial
activities (Almalki et al, 2017)
Antihelmintic activity of turmeric 
powder (Singh et al, 2017)
Inhibitory effects on Influenza 
A virus (Dao et al, 2012)
Antioxidant effects of essential 
oil (Avanco et al, 2017)
Inhibit biofilms development 
(Packiavathy et al, 2014)

T. evansi stock




















Orally administered of 0.2 mL 100 mg/kg bw of   
freeze-dried Curcuma longa aqueous extract
T. evansi administered i.p.
(5 × 103 T. evansi / mice)
Flow Chart
Experimental Design
GROUP REGIME DESCRIPTION Curcuma longa DOSAGE
TREATMENT
PREVENTIVE
14 days pre-infection 0.2 mL 100 mg/kg bw aqueous-extract
7 days pre-infection 0.2 mL 100 mg/kg bw aqueous-extract
3 days pre-infection 0.2 mL 100 mg/kg bw aqueous-extract
CURATIVE
3 days post-infection 0.2 mL 100 mg/kg bw aqueous-extract
5 days post-infection 0.2 mL 100 mg/kg bw aqueous-extract
7 days post-infection 0.2 mL 100 mg/kg bw aqueous-extract
GROUP REGIME DESCRIPTION CONTROL DOSAGE
CONTROL
POSITIVE Berenil (Sigma-Aldrich KL) 0.01 mL 3.5 mg/kg bw
NEGATIVE 0.9 % Normal Saline 0.1 mL  0.9 normal saline




Parasite Administration And Animal Tagging 
(A) (B) (C)
(D)
Giemsa Staining And Microscopic Observation
(E) (F)
(A)


























































Parasite Survival In PRE14 Mice Group : 70th Day
Giemsa thin blood smear of the mice from PRE14 mice group taken on day 70
post-infection as observed under x100 magnification of light microscope (A)
and x5000 magnification of SEM (Phillips XL30, UK) (B)
(A) (B)(B)
DAY 70
PARASITE SURVIVAL IN PRO1 GROUP: ON 115th DAY
(A) (B)
arasite Survival n PRE14 Mice Group 100th Day
DAY 100
Giemsa thin blood smear of the mice from PRE14 mice group taken on day
100 post-infection as observed under x100 magnification of light microscope
(A) and x5000 magnification of SEM (Phillips XL30, UK) (B)
(A) (B)(B)
Parasite Survival In PRE14 Mice Group : 130th Day
DAY 130
Giemsa thin blood smear of the mice from PRE14 mice group taken on day
130 post-infection as observed under x100 magnification of light microscope
(A) and x5000 magnification of SEM (Phillips XL30, UK) (B)
(B)(A) ( )
Parasite Survival In PRE14 Mice Group : 160th Day
DAY 160
Giemsa thin blood smear of the mice from PRE14 mice group taken on day
160 post-infection as observed under x100 magnification of light microscope
(A) and x4000 magnification of SEM (Phillips XL30, UK) (B)
(B)(A) ( )
Parasite Survival In PRE14 Mice Group : 190th Day
DAY 190
Giemsa thin blood smear of the mice from PRE14 mice group taken on day
190 post-infection as observed under x100 magnification of light microscope
(A) and x5000 magnification of SEM (Leo 1450VP, Japan) (B)
(A) (B)
DAY 220
Parasite Survival In PRE14 Mice Group : 220th Day
Giemsa thin blood smear of the mice from PRE14 mice group taken on day
220 post-infection as observed under x100 magnification of light microscope
(A) and x4600 magnification of SEM (Leo 1450VP, Japan) (B)
(B)







Parasite Growth in Berenil-Treated Group (POS)
(4A)
(4B)




T. cucumerina VS Berenil
(4B) (5B) (6B)
(B)
Scanning electron micrograph showed the morphological changes of
T. evansi in PRE14 mice (0.2 mL 100 mg/kg bw Curcuma longa aqueous-extract)
on 220th day post infection (A) and in POS mice at 6th hours post treatment
(0.01mL 3.5 mg/kg bw Berenil) (B) as observed under x5000 magnification of SEM
(A)
Curcuma longa : 220th day Berenil : 6th hours
Biochemical Test For Toxicity Assessment
(A)






















































6.80   
± 3.06
5.8 – 9.5 g/dL
TA : Sub-acute regime – Daily treatment (28 days) 
TB : Sub-acute regime – Daily treatment (28 days) 2 hours post-infection
TC : Sub-chronic regime – Daily treatment (90 days)
TD : Sub-chronic regime – Daily treatment (90 days) 2 hours post-infection
CN : Control regime – Normal mice without infection and treatment
CI : Control regime – Infected mice on D0
ALT : Alanine aminotransferase
AST : Aspartate transaminase
ALP : Alkaline phosphatase
STP : Serum total protein
(*) All values were expressed as  
mean ± standard deviation (sd)




Treatment (Acute) Treatment (Sub-Acute) Control

Hypothesis
• Longer prophylactic duration  longer survival period of the host.
• New wave of infection  mice is susceptible to infection (Kurup and
Rajamohan 2011).
• Curative regime are less effective than other treatment regimens
• The action of β-turmerone (C15H22O) molecule in Curcuma longa against –
thiol group of parasite enzymes in which crucial for parasite proliferation
(Ma et al. 2012).
• Bioactive compound of isocurcumenol (C15H22O2) in Curcuma longa
inhibited the proteinase, thioredoxin reductase (Zhao et al. 2010)
• Compound α-curzerene (C15H20O) in Curcuma longa rhizomes interfered
sugar absorption process in Leishmania donovani (Voon et al. 2014)
Absolute Hypothesis
EAT TURMERIC..!
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Rationale Of The Study
Reliability of Anti-Trypanosomial Drugs
• Resistant issues in India, Thailand & Indonesia 
• Unaffordable  expensive in certain regions
• Wrong dosage & concentration  side effects
Economic Growth & Biotechnology Sector
• Biotechnology  main focus in the next decade
• Turmeric  consumable & easily manipulated 
• AHT & Surra  influenced productivity of human & livestock
Current Issues of T. evansi
• Trans-host boundary : animal  human (Assam India 2008)
(A) (B)
Parasite Survival In PRE14 Mice Group : 225th Day
(A) (B)
DAY 225
Reemerged of T. evansi which survived in PRE14 group mice on day 225
due to the action of ‘variable surface glycoprotein (VSA) stochastic genetic
modification’ as observed under x100 magnification of light microscope (A)
and x1600 magnification of SEM (Leo 1450VP, Japan) (B).
(A) (B)
Parasite Survival In PRE14 Mice Group : 205th Day
Reemerged of T. evansi which survived in PRE14 group mice on day 227 due to
the action of ‘variable surface glycoprotein (VSA) stochastic genetic modification’
as observed under x100 magnification of light microscope (A) and x2300
magnification of SEM (Leo 1450VP, Japan) (B). Later the mice died on day 228
(B)(A)
DAY 227 
‘Variable Surface Glycoprotein’  (VSG)
- Survival factor of Trypanosoma spp. in the infected host
- High density layer on the parasite cell membrane
- Contained 1 x 109 similar & uniformed glycoprotein 
molecules expressed by VSG-Trypanosome gene
- Protect the parasite from being identified/action of the 
host immune system 
- Similar & uniformed glycoprotein molecule  only end 
region of `N-terminal loops’ structure (300-500 amino 
acid structures) can be identified by the host immune 
systems  specific antibody-antigen mechanisms
‘Variable Surface Glikoprotein’  (VSG) – cont.
- When the end region of `N-terminal loops’ structure 
being identified by the host immune systems  VSG-
stochastic genetic modification’ of the parasite plays the 
role.
- VSG stochastic genetic modification = periodic changes 
of antigenic variation  the structures & characteristics 
of parasite cell membrane was modified whenever 
confronted with the host’s specific immune system 
which may varies.
- Periodic changes of antigenic variation  changes in 
parasitemia waves  longer survival time of the 
parasite  chronic infection on host
Effectuation of the changes in host’s specific immune system
Survival Pattern of the Trypanosomiasis Infected-Host Due 
to VSG-Stochastic Genetic Modification Phenomenon
Mechanism of Trypanosome VSG-stochastic genetic modification
Day of 
Infection
(*) 
Latent Period(*) 
